Skip to main content

Month: March 2023

Stitch Fix Announces Second Quarter of Fiscal Year 2023 Financial Results: Raises Full Year FY23 Adj. EBITDA Guidance; Announces CFO Transition

SAN FRANCISCO, March 07, 2023 (GLOBE NEWSWIRE) — Stitch Fix, Inc. (NASDAQ:SFIX), the trusted online personal stylist, today announced its financial results for the second quarter of fiscal year 2023 ended January 28, 2023. Stitch Fix Interim CEO Katrina Lake said, “This quarter, we continued to execute on our plan to achieve profitability and preserve liquidity, delivering adjusted EBITDA of $3.8 million, which is at the high end of our guidance range. Looking forward, we will continue to invest in the advanced data science and machine learning capabilities combined with personalized styling expertise that have set us apart for more than a decade. This strategic re-focusing on our styling-first model will deliver clarity to the client experience and drive efficiency in our marketing spend. We’re proud to have helped millions of...

Continue reading

Full House Resorts Announces Fourth Quarter Results

– The Temporary by American Place Officially Opened on February 17th; Illinois Sports Skin Expected to Commence Operations in the Coming Months – Construction Continues at Chamonix Casino Hotel, with an Opening Expected in the Second Half of 2023 – Executed New Sports Skin Agreement in Colorado – Lease Agreement to Operate Grand Lodge Casino in Lake Tahoe Extended to December 31, 2024 – Completed a $40 Million Bond Deal in February, Further Ensuring That No Additional Capital Will be Required Prior to Arranging Financing for the Permanent American Place Casino LAS VEGAS, March 07, 2023 (GLOBE NEWSWIRE) — Full House Resorts, Inc. (Nasdaq: FLL) today announced results for the fourth quarter and year ended December 31, 2022, including updates regarding its growth pipeline. “On February 17th, The Temporary...

Continue reading

Synchronoss Technologies Reports Fourth Quarter and Full Year 2022 Results

Income from Operations of $1.3 Million Versus Loss of $19.0 Million in 2021 Net Cash Provided by Operating Activities of $17.4 Million in 2022, a $12.4 Million Improvement from 2021 Eleventh Consecutive Quarter of Double-Digit Cloud Subscriber Growth and Invoiced Cloud Revenue Growth of 9.5% in Q4 Underscore Strength in Core Operations Management Introduces 2023 Guidance BRIDGEWATER, N.J., March 07, 2023 (GLOBE NEWSWIRE) — Synchronoss Technologies Inc. (“Synchronoss” or the “Company”) (Nasdaq: SNCR), a global leader and innovator in cloud, messaging, and digital products and platforms, today reported financial results for its fourth quarter and full year ended December 31, 2022. Fourth Quarter and Recent Operational HighlightsAnnounced 14% year-over-year Cloud subscriber growth for the fourth quarter of 2022. The eleventh consecutive...

Continue reading

AAR to announce third quarter fiscal year 2023 results on March 21, 2023

Wood Dale, Illinois, March 07, 2023 (GLOBE NEWSWIRE) — AAR CORP. (NYSE: AIR), a leading provider of aviation services to commercial and government operators, MROs, and OEMs, today announced that it will release financial results for its third quarter of fiscal year 2023, ended February 28, 2023, after the close of the New York Stock Exchange trading session on Tuesday, March 21, 2023. On Tuesday, March 21, 2023, at 3:45 p.m. Central time, AAR will hold a conference call to discuss the results. The conference call can be accessed by registering at https://register.vevent.com/register/BI9cbe1c3098294c4c87bdcf35609d3f2c. Once registered, participants will receive a dial-in number and a unique PIN that will allow them to access the call. A replay of the conference call will be available for on-demand listening shortly after the completion...

Continue reading

Weyco Reports Fourth Quarter And Full Year 2022 Results

MILWAUKEE, March 07, 2023 (GLOBE NEWSWIRE) — Weyco Group, Inc. (NASDAQ: WEYS) (“we,” “our,” “us” and the “Company”) today announced financial results for the quarter and year ended December 31, 2022. Fourth Quarter 2022Consolidated net sales were $99.0 million, down 2% from $101.4 million in the fourth quarter of 2021. Consolidated gross earnings increased to 46.6% of net sales compared to 40.2% of net sales in last year’s fourth quarter, due to higher gross margins in our North American wholesale segment. Quarterly operating earnings rose to a record $15.1 million, up 18% compared to $12.8 million in the fourth quarter of 2021. Fourth-quarter 2022 net earnings were $10.2 million, or $1.06 per diluted share, compared to $10.3 million, or $1.07 per diluted share, last year. North American Wholesale Segment Fourth quarter wholesale...

Continue reading

Profound Medical Announces Fourth Quarter and Full Year 2022 Financial Results

Company confirms Current Procedural Terminology (“CPT®”) Category 1 application for TULSA TORONTO, March 07, 2023 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2022. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. “Our U.S. TULSA business, both in terms of installed base growth and existing system utilization, has increasingly become the primary driver of our recurring revenue...

Continue reading

Treace Medical Concepts Reports Fourth Quarter and Full Year 2022 Financial Results

PONTE VEDRA, Fla., March 07, 2023 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights:Revenue of $49.8 million in the fourth quarter of 2022, a 49% increase over the same period last year and a 51% increase sequentially. Full year 2022 revenue of $141.8 million increased 50% over 2021. Blended average revenue per Lapiplasty® procedure kit sold was $5,907, a 10% increase over the same period last year and a 2% increase sequentially. Full year 2022 blended average revenue per Lapiplasty® procedure kit sold of $5,753 increased 7% over 2021. Gross margin...

Continue reading

Sumo Logic Announces Fourth Quarter and Fiscal Year 2023 Financial Results

Fourth quarter revenue grew 19% year over year to $79.8 millionFull year fiscal 2023 revenue grew 24% year over year to $300.7 millionFull year fiscal 2023 ARR grew 17% year over year to $301.6 million REDWOOD CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) — Sumo Logic (NASDAQ: SUMO), the SaaS analytics platform to enable reliable and secure cloud-native applications, today announced financial results for the fourth quarter and fiscal year 2023 ended January 31, 2023. Fourth Quarter Fiscal 2023 Financial HighlightsRevenue was $79.8 million, an increase of 19% year over year GAAP gross margin was 72%; non-GAAP gross margin was 75% GAAP operating loss was $28.1 million; GAAP operating margin was (35)% Non-GAAP operating loss was $4.0 million; non-GAAP operating margin was (5)% GAAP net loss was $27.9 million, or $0.23 per share Non-GAAP...

Continue reading

BioSyent Announces Launch of New FeraMAX® Pd Maintenance 45

FeraMAX Pd Maintenance 45 FeraMAX Pd Maintenance 45MISSISSAUGA, Ontario, March 07, 2023 (GLOBE NEWSWIRE) — On the eve of International Women’s Day, BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) celebrates the Canadian launch of FeraMAX® Pd Maintenance 45 by its subsidiary, BioSyent Pharma Inc. FeraMAX® Pd Maintenance 45 is BioSyent’s third product incorporating Polydextrose-Iron Complex (PDIC), a patented oral iron supplement delivery system. The FeraMAX® Pd family of products continues the innovation history of FeraMAX® and strengthens BioSyent’s commitment to women’s health and the management of iron health across various life stages. Iron deficiency disproportionally affects women and children and is an independent risk factor for decreased quality of life and increased morbidity and mortality.i “My personal...

Continue reading

Fresh Tracks Therapeutics Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02

FRTX-02 was generally safe and well tolerated within the potential therapeutic dose range, meeting the study’s primary objectives Plasma concentrations within the potential therapeutic dose range were consistent with efficacious exposure levels established in nonclinical disease models and support once-daily oral dosing Reduction in disease-relevant cytokines was observed in exploratory ex-vivo LPS-stimulated whole blood pharmacodynamic assays Topline results support the continued development of FRTX-02 as a potential first-in-class, once-daily oral treatment for atopic dermatitis and/or other autoimmune diseases Evaluating strategic options to further develop FRTX-02 and maximize shareholder value BOULDER, Colo., March 07, 2023 (GLOBE NEWSWIRE) — Fresh Tracks Therapeutics, Inc. (“Fresh Tracks” or the “Company”) (Nasdaq: FRTX),...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.